An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice
Lymphoma, B-Cell, Lymphoma, Follicular
Conditions: official terms
Lymphoma, B-Cell - Lymphoma, Follicular
Study Type
Study Phase
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Overall Status
This observational study aims to assess the therapeutic responsiveness of MabThera SC in patients with malignant lymphomas under everyday clinical practice conditions. Patients with previously untreated CD-20 positive follicular non-Hodgkin's lymphoma (NHL) or previously untreated CD-20 positive diffuse large B-cell lymphoma (DLBCL) who are planned for therapy with MabThera SC according to the assessment of the physician will be prospectively enrolled for observation. No study specific measures are required; treatment and documentation will be performed according to usual clinical practice.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Women and men aged >=18 years

- Previously untreated CD-20 positive follicular NHL

- Previously untreated CD-20 positive DLBCL

- Planned therapy with MabThera SC according to the assessment of the physician (before the start and independent from this study)

- Suitability for the therapy with MabThera SC

Exclusion Criteria:

All contraindications, interactions and incompatibilities for therapy with MabThera SC
Villingen-Schwenningen, Germany
Status: Recruiting
Start Date
July 2014
Completion Date
December 2018
Hoffmann-La Roche
Hoffmann-La Roche
Record processing date processed this data on July 28, 2015 page